ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Price, Forecast & Analysis
USA - NASDAQ:RARE - US90400D1081 - Common Stock
RARE Key Statistics, Chart & Performance
The current stock price of RARE is 33.53 USD. In the past month the price increased by 0.3%. In the past year, price decreased by -25.07%.
RARE Latest News, Press Relases and Analysis
RARE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About RARE
Company Profile
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,294 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Company Info
ULTRAGENYX PHARMACEUTICAL IN
60 Leveroni Ct
Novato CALIFORNIA 94949 US
CEO: Emil D. Kakkis
Employees: 1294
Phone: 14154838800
ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ
What does ULTRAGENYX PHARMACEUTICAL IN do?
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,294 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
What is the stock price of ULTRAGENYX PHARMACEUTICAL IN today?
The current stock price of RARE is 33.53 USD. The price increased by 0.84% in the last trading session.
Does ULTRAGENYX PHARMACEUTICAL IN pay dividends?
RARE does not pay a dividend.
What is the ChartMill technical and fundamental rating of RARE stock?
RARE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ULTRAGENYX PHARMACEUTICAL IN (RARE) based on its PE ratio?
ULTRAGENYX PHARMACEUTICAL IN (RARE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.94).
Is ULTRAGENYX PHARMACEUTICAL IN (RARE) expected to grow?
The Revenue of ULTRAGENYX PHARMACEUTICAL IN (RARE) is expected to grow by 20.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the outstanding short interest for ULTRAGENYX PHARMACEUTICAL IN?
The outstanding short interest for ULTRAGENYX PHARMACEUTICAL IN (RARE) is 9.47% of its float.
RARE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to RARE. When comparing the yearly performance of all stocks, RARE is a bad performer in the overall market: 74.53% of all stocks are doing better.
RARE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RARE. RARE may be in some trouble as it scores bad on both profitability and health.
RARE Financial Highlights
Over the last trailing twelve months RARE reported a non-GAAP Earnings per Share(EPS) of -5.94. The EPS increased by 8.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.71% | ||
| ROE | -6330.7% | ||
| Debt/Equity | 83.39 |
RARE Forecast & Estimates
27 analysts have analysed RARE and the average price target is 85.47 USD. This implies a price increase of 154.89% is expected in the next year compared to the current price of 33.53.
For the next year, analysts expect an EPS growth of 18.8% and a revenue growth 20.05% for RARE